AU2016374643B2 - Therapeutic methods using erythrocytes - Google Patents

Therapeutic methods using erythrocytes Download PDF

Info

Publication number
AU2016374643B2
AU2016374643B2 AU2016374643A AU2016374643A AU2016374643B2 AU 2016374643 B2 AU2016374643 B2 AU 2016374643B2 AU 2016374643 A AU2016374643 A AU 2016374643A AU 2016374643 A AU2016374643 A AU 2016374643A AU 2016374643 B2 AU2016374643 B2 AU 2016374643B2
Authority
AU
Australia
Prior art keywords
cells
red blood
cell
rbcs
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016374643A
Other languages
English (en)
Other versions
AU2016374643A1 (en
Inventor
Ben Herbert
Cameron Hill
Elisabeth KARSTEN
Alan Liddle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangui Bio Pty Ltd
Original Assignee
Sangui Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905309A external-priority patent/AU2015905309A0/en
Application filed by Sangui Bio Pty Ltd filed Critical Sangui Bio Pty Ltd
Publication of AU2016374643A1 publication Critical patent/AU2016374643A1/en
Application granted granted Critical
Publication of AU2016374643B2 publication Critical patent/AU2016374643B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/25—Urinary tract cells, renal cells
    • C12N2502/256—Renal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016374643A 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes Active AU2016374643B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905309 2015-12-22
AU2015905309A AU2015905309A0 (en) 2015-12-22 Therapeutic methods using erythrocytes
PCT/AU2016/000404 WO2017106899A2 (en) 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes

Publications (2)

Publication Number Publication Date
AU2016374643A1 AU2016374643A1 (en) 2018-07-05
AU2016374643B2 true AU2016374643B2 (en) 2023-12-14

Family

ID=59088638

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016374643A Active AU2016374643B2 (en) 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes

Country Status (9)

Country Link
US (1) US11564948B2 (enExample)
EP (1) EP3393482A4 (enExample)
JP (2) JP2018538343A (enExample)
KR (1) KR20180102096A (enExample)
CN (1) CN108883133A (enExample)
AU (1) AU2016374643B2 (enExample)
CA (1) CA3009369A1 (enExample)
SG (1) SG11201805052YA (enExample)
WO (1) WO2017106899A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852672C (en) 2011-10-17 2021-07-20 Massachusetts Institute Of Technology A microfluidic system and method for delivering a payload into a cell by causing perturbations in a cell membrane of the cell
JP6502940B2 (ja) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー 細胞への物質の選択的送達
RU2020139190A (ru) 2014-10-31 2021-01-26 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
CA2964138C (en) 2014-11-14 2023-11-14 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
US11125739B2 (en) 2015-01-12 2021-09-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
EP3320082B1 (en) 2015-07-09 2023-05-24 Massachusetts Institute of Technology Delivery of materials to anucleate cells
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP4009047A1 (en) 2015-10-07 2022-06-08 Sangui Bio Pty. Ltd Blood preparation and profiling
JP2020502545A (ja) * 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ． エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング
BR112023018294A2 (pt) * 2021-03-10 2023-12-12 Terasaki Inst For Biomedical Innovation Fatores de crescimento para carne cultivada em laboratório e outras aplicações

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019317A1 (en) * 2007-08-08 2009-02-12 Erytech Pharma Composition and therapeutic anti-tumour vaccine
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
US20120195869A1 (en) * 1999-08-30 2012-08-02 Terman David S Sickled Erythrocytes with Anti-tumor Agents Induce Tumor Vaso-occlusion and Tumoricidal Effects

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
FR2778851B1 (fr) * 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
EP1355656A2 (en) * 2000-07-24 2003-10-29 Gendel Limited Red blood cell as vehicle for agent-membrane translocation sequence conjugate
EP1495328B1 (en) 2002-04-16 2014-06-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A marker for measuring liver cirrhosis
GB0325483D0 (en) 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US20060166223A1 (en) 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
WO2006123253A2 (en) 2005-03-29 2006-11-23 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer
US20110245092A1 (en) 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
CN112280739A (zh) * 2008-05-06 2021-01-29 安斯泰来再生医药协会 用于制备衍生自多能干细胞的去核类红细胞的方法
EP2442641A4 (en) * 2009-06-16 2016-03-09 Univ Columbia METHOD FOR REDUCING SIDE EFFECTS OF THE TRANSFUSION OF AGED RED BLOOD CELLS
WO2011018288A1 (en) 2009-08-13 2011-02-17 Basf Se Means and methods for diagnosingthyroid disorders
WO2011127056A2 (en) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose
SG195180A1 (en) 2011-05-31 2013-12-30 Singapore Health Serv Pte Ltd Method for detecting disease biomarkers
CN103687940B (zh) * 2011-07-06 2016-10-12 希司托赛尔有限公司 用于间充质干细胞的处理方法及其在氧化应激相关疾病治疗中的应用
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
SG11201405919QA (en) * 2012-03-21 2014-10-30 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
HU230341B1 (hu) * 2012-04-20 2016-02-29 Advancell Diagnosztika Kft. A vörösvérsejt-membrán kvantitatív biomarkerei
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
US10272115B2 (en) * 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
MX374129B (es) 2013-05-10 2025-03-05 Erydel Spa Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.
JP6383920B2 (ja) 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
US10273455B2 (en) * 2014-04-07 2019-04-30 Iucf-Hyu In vitro expansion of erythroid cells
CN114748503B (zh) 2015-05-18 2025-09-30 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
EP4009047A1 (en) 2015-10-07 2022-06-08 Sangui Bio Pty. Ltd Blood preparation and profiling
JP2020502545A (ja) 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ． エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120195869A1 (en) * 1999-08-30 2012-08-02 Terman David S Sickled Erythrocytes with Anti-tumor Agents Induce Tumor Vaso-occlusion and Tumoricidal Effects
WO2009019317A1 (en) * 2007-08-08 2009-02-12 Erytech Pharma Composition and therapeutic anti-tumour vaccine
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Also Published As

Publication number Publication date
US11564948B2 (en) 2023-01-31
CN108883133A (zh) 2018-11-23
WO2017106899A2 (en) 2017-06-29
SG11201805052YA (en) 2018-07-30
KR20180102096A (ko) 2018-09-14
JP2021155454A (ja) 2021-10-07
WO2017106899A3 (en) 2017-09-28
EP3393482A4 (en) 2019-08-21
AU2016374643A1 (en) 2018-07-05
JP2018538343A (ja) 2018-12-27
EP3393482A2 (en) 2018-10-31
US20190000884A1 (en) 2019-01-03
CA3009369A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
AU2016374643B2 (en) Therapeutic methods using erythrocytes
Bobis-Wozowicz et al. Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles
Fekete et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components
CN113677789B (zh) 免疫调节性间充质干细胞
CN103436493B (zh) 雷帕霉素诱导调节性γδT细胞的培养方法
JP2022539249A (ja) 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法
de Haar et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
Tei et al. TLR3-driven IFN-β antagonizes STAT5-activating cytokines and suppresses innate type 2 response in the lung
Ikeda et al. Transcriptional analysis of intravenous immunoglobulin resistance in Kawasaki disease using an induced pluripotent stem cell disease model
CN115322968A (zh) 一种car-t细胞的培养体系及应用和培养方法
CN115044555A (zh) 一种人脐血造血干细胞体外扩增和维持干性用培养基
Kim et al. CD26 inhibition potentiates the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells by delaying cellular senescence
CN114990063A (zh) 促进造血干祖细胞迁移、归巢和植入的组合物及其应用
Takacs et al. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+ myeloid cells into the tumor microenvironment in a redundant manner
EP1751661B1 (en) Method for selectively expanding, selecting and enriching stem/progenitor cell populations
JP6058802B2 (ja) 免疫調節細胞の作出方法
RU2828728C2 (ru) Иммуномодулирующие мезенхимальные стволовые клетки
CN105624104B (zh) 一种提高人间充质干细胞功能的细胞处理方法
TWI486449B (zh) 製備免疫調節細胞之方法、依該方法所製備之細胞及其應用
CN119410589A (zh) 一种小鼠干性car-t细胞、及其制备方法和应用
WO2022098718A1 (en) Modified nk cells with reduced ccr5 expression and methods of their use
CN119351330A (zh) 一种诱导分化形成巨噬细胞的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)